Arecor Therapeutics plc (AREC.L)

116.00 -11.50 (-9.02%) As of 03:58PM BST. Market open.

Arecor Therapeutics plc

Chesterford Research Park
Little Chesterford CB10 1XL
United Kingdom
44 1223 426 060
https://arecor.com

Sector(s): Healthcare
Industry: Biotechnology
Full-time employees: 

Key executives

Name	Title	Pay	Exercised	Year born
Dr. Sarah Jennifer Howell Ph.D.	CEO & Director	421k	51.46k	1975
Ms. Susan Day Lowther FCMA	CFO, Company Secretary & Director	306k	154.38k	1960
Dr. Jan Jezek Ph.D.	Chief Scientific Officer	N/A	N/A	N/A
Mr. David Gerring	Senior Vice President of Development	N/A	N/A	N/A
Dr. Manjit Rahelu Ph.D.	Chief Business Officer	N/A	N/A	N/A

Amounts are as of 31 December 2022, and compensation values are for the last fiscal year ending on that date. Pay includes salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in GBp.

Description

Arecor Therapeutics plc, a biopharmaceutical company, focuses on developing products in diabetes and other indications. The company through its proprietary formulation technology platform, Arestat, developing a portfolio of proprietary products in diabetes and other indications, as well as working with pharmaceutical and biotechnology companies to deliver enhanced reformulations of therapeutic products. It also offers Ogluo, a ready-to-use glucagon auto-injector pen that is used to treat hypoglycaemia in patients with diabetes; and specialty hospital care products. In addition, the company is developing AT247, an ultra-rapid acting insulin for patients with Type I and Type II diabetics; and AT278, an ultra-concentrated rapid acting insulin formulation that has been designed to accelerate the absorption of insulin post injection. It has a research collaboration with TRx Biosciences Limited for the formulation development of an oral glucagon-like peptide-1 (GLP-1) receptor agonist product; and Medtronic plc to develop a novel, high concentration, thermostable insulin for use by Medtronic's Diabetes business in a next-generation implantable pump. The company was founded in 2007 and is headquartered in Little Chesterford, the United Kingdom.

Corporate governance

Arecor Therapeutics plc’s ISS governance QualityScore as of N/A is N/A. The pillar scores are Audit: N/A; Board: N/A; Shareholder rights: N/A; Compensation: N/A.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while 10 indicates higher governance risk.